Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Plast Reconstr Surg ; 153(2): 424e-441e, 2024 02 01.
Article in English | MEDLINE | ID: mdl-38266139

ABSTRACT

BACKGROUND: The American Society of Plastic Surgeons commissioned the multidisciplinary Performance Measure Development Work Group on Reconstruction after Skin Cancer Resection to identify and draft quality measures for the care of patients undergoing skin cancer reconstruction. Included stakeholders were the American Academy of Otolaryngology-Head and Neck Surgery, the American Academy of Facial Plastic and Reconstructive Surgery, the American Academy of Dermatology, the American Society of Dermatologic Surgery, the American College of Mohs Surgery, the American Society for Mohs Surgery, and a patient representative. METHODS: Two outcome measures and five process measures were identified. The outcome measures included the following: (1) patient satisfaction with information provided by their surgeon before their facial procedure, and (2) postprocedural urgent care or emergency room use. The process measures focus on antibiotic stewardship, anticoagulation continuation and/or coordination of care, opioid avoidance, and verification of clear margins. RESULTS: All measures in this report were approved by the American Society of Plastic Surgeons Quality and Performance Measures Work Group and Executive Committee, and the stakeholder societies. CONCLUSION: The work group recommends the use of these measures for quality initiatives, Continuing Medical Education, Continuous Certification, Qualified Clinical Data Registry reporting, and national quality reporting programs.


Subject(s)
Skin Neoplasms , Surgeons , Humans , Skin Neoplasms/surgery , Skin , Mohs Surgery , Academies and Institutes
2.
Cutis ; 112(3): 116-119, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37903396

ABSTRACT

The first annual Association of Professors of Dermatology (APD) program director (PD) survey was distributed in November 2022 and included 53 respondents from individual Accreditation Council for Graduate Medical Education (ACGME) programs. This survey included 137 in-depth questions to identify similarities and differences among programs regarding 12 broad categories: program characteristics; PD demographics; impact of the COVID-19 pandemic on residency training; available resources; quality improvement; clinical instruction; didactic instruction; research content; diversity, equity, and inclusion; wellness; evaluation systems; and graduation outcomes of postgraduate year (PGY) 4 residents. The survey provided preliminary insight to similarities and differences between programs, such as varying academic time and research resources, while also challenging norms seen in areas of diversity, equity, and inclusion. As future surveys are optimized to obtain greater response rates, these metrics can be captured in a centralized database accessible to PDs to reflect trends and identify strengths and weaknesses of dermatology residency programs.


Subject(s)
Dermatology , Internship and Residency , Humans , United States , Pandemics , Education, Medical, Graduate , Surveys and Questionnaires
4.
Am J Clin Dermatol ; 23(6): 749-753, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35930133

ABSTRACT

Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory skin disease that is often recalcitrant to multiple treatments. In determining biologic candidacy for patients with HS, we propose a paradigm shift away from Hurley staging and towards consideration of other variables. Biologics represent a long-term treatment option for HS that may serve as a disease-modifying agent. These medications are typically initiated in patients with moderate to severe disease, which, based on inclusion criteria in clinical trials, is often defined as Hurley stage II or III disease, at which point irreversible tissue damage has already occurred. In real-world clinical settings, these considerations include treatments tried and failed, predicted disease trajectory, disease characteristics beyond lesion type, impact of disease on patients' functional status and quality of life, and patient comorbidities, venturing away from the limitations of Hurley stage designations. Future clinical trials may benefit from inclusion of recalcitrant Hurley stage I patients, which may then re-shape treatment guidelines and insurance coverage and improve patient access to biologic treatments.


Subject(s)
Biological Products , Hidradenitis Suppurativa , Biological Products/therapeutic use , Hidradenitis Suppurativa/drug therapy , Humans , Quality of Life , Severity of Illness Index , Skin
5.
J Am Acad Dermatol ; 86(5): 1092-1101, 2022 05.
Article in English | MEDLINE | ID: mdl-33493574

ABSTRACT

BACKGROUND: Hidradenitis suppurativa (HS) is associated with comorbidities that contribute to poor health, impaired life quality, and mortality risk. OBJECTIVE: To provide evidence-based screening recommendations for comorbidities linked to HS. METHODS: Systematic reviews were performed to summarize evidence on the prevalence and incidence of 30 comorbidities in patients with HS relative to the general population. The screening recommendation for each comorbidity was informed by the consistency and quality of existing studies, disease prevalence, and magnitude of association, as well as benefits, harms, and feasibility of screening. The level of evidence and strength of corresponding screening recommendation were graded by using the Strength of Recommendation Taxonomy (SORT) criteria. RESULTS: Screening is recommended for the following comorbidities: acne, dissecting cellulitis of the scalp, pilonidal disease, pyoderma gangrenosum, depression, generalized anxiety disorder, suicide, smoking, substance use disorder, polycystic ovary syndrome, obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, hypertension, cardiovascular disease, inflammatory bowel disease, spondyloarthritis, and sexual dysfunction. It is also recommended to screen patients with Down syndrome for HS. The decision to screen for specific comorbidities may vary with patient risk factors. The role of the dermatologist in screening varies according to comorbidity. LIMITATIONS: Screening recommendations represent one component of a comprehensive care strategy. CONCLUSIONS: Dermatologists should support screening efforts to identify comorbid conditions in HS.


Subject(s)
Hidradenitis Suppurativa , Metabolic Syndrome , Pyoderma Gangrenosum , Canada/epidemiology , Comorbidity , Female , Hidradenitis Suppurativa/diagnosis , Hidradenitis Suppurativa/epidemiology , Hidradenitis Suppurativa/etiology , Humans , Metabolic Syndrome/epidemiology , Pyoderma Gangrenosum/epidemiology
6.
Cutis ; 100(2): 92-93, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28961292

ABSTRACT

Patients with delusional infestation frequently bring specimens and examining these specimens is important in establishing a therapeutic relationship. The minute brown scavenger beetle is a member of the family Latridiidae. It is found in moist environments and feeds on mold. It poses no threat to humans, but it is important that dermatologists recognize it because it may be contained in specimens brought by patients.


Subject(s)
Coleoptera , Delusional Parasitosis/diagnosis , Skin Diseases, Parasitic/diagnosis , Animals , Delusional Parasitosis/psychology , Dermatologists , Humans , Skin Diseases, Parasitic/psychology
7.
IDCases ; 6: 72-73, 2016.
Article in English | MEDLINE | ID: mdl-27752471

ABSTRACT

A 61 year old immunosuppressed male presented with a non-healing wound following a rose thorn injury. Initial cultures revealed Candida parapsilosis, however histology confirmed squamous cell carcinoma in-situ (SCCis). This case emphasizes the importance of biopsy and cultures as fungal infection and SCCis often have similar, non-specific clinical appearances.

8.
Case Rep Dermatol Med ; 2016: 7137691, 2016.
Article in English | MEDLINE | ID: mdl-28101384

ABSTRACT

Background. Acrokeratosis paraneoplastica, or Bazex syndrome, is a paraneoplastic syndrome characterized by cutaneous psoriasiform lesions with associated acral erythema and scale, as well as nail changes, including onycholysis and ungual dystrophy. Its most advanced, severe form involves the trunk, elbows, and knees. It is typically associated with upper aerodigestive tract malignancies in males. Rare cases associated with gynecological cancers have been reported, including uterine adenocarcinoma, as well as ovarian and vulvar squamous cell carcinomas. Cutaneous manifestations often precede cancer diagnosis. In most reported cases, skin changes resolve when the underlying malignancy is adequately treated. Main Observations. We present the case of a 56-year-old female diagnosed with acrokeratosis paraneoplastica following the discovery of FIGO stage IIB cervical squamous cell carcinoma (SCC). Scaling, hyperpigmentation, xerosis, and fissuring were noted on the patient's hands, feet, legs, arms, and lower back. Pitting was noted on her fingernails. Her cervical cancer was successfully treated with chemoradiotherapy, after which her cutaneous lesions persisted for two months before resolving. Conclusions. The presentation of acrokeratosis paraneoplastica in this context is atypical. Reports of associations with gynecological cancers, as in our patient's case, are exceedingly rare.

SELECTION OF CITATIONS
SEARCH DETAIL
...